BlackRock’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-7,356,721
| Closed | -$82.6M | – | 5612 |
|
|
2025
Q2 | $82.6M | Sell |
7,356,721
-521,515
| -7% | -$2.97M | ﹤0.01% | 2169 |
|
|
2025
Q1 | $36M | Buy |
7,878,236
+352,766
| +5% | +$2.36M | ﹤0.01% | 2565 |
|
|
2024
Q4 | $42.4M | Buy |
7,525,470
+249,123
| +3% | +$1.41M | ﹤0.01% | 2556 |
|
|
2024
Q3 | $35.2M | Buy |
7,276,347
+656,343
| +10% | +$3.81M | ﹤0.01% | 2687 |
|
|
2024
Q2 | $32.3M | Buy |
6,620,004
+1,246,827
| +23% | +$7.84M | ﹤0.01% | 2700 |
|
|
2024
Q1 | $71.4M | Buy |
5,373,177
+937,696
| +21% | +$12.4M | ﹤0.01% | 2251 |
|
|
2023
Q4 | $61.8M | Buy |
4,435,481
+437,082
| +11% | +$5.42M | ﹤0.01% | 2350 |
|
|
2023
Q3 | $53M | Buy |
3,998,399
+151,696
| +4% | +$2.44M | ﹤0.01% | 2369 |
|
|
2023
Q2 | $72.1M | Buy |
3,846,703
+300,218
| +8% | +$5M | ﹤0.01% | 2267 |
|
|
2023
Q1 | $51.1M | Sell |
3,546,485
-47,589
| -1% | -$932K | ﹤0.01% | 2426 |
|
|
2022
Q4 | $69.5M | Buy |
3,594,074
+217,864
| +6% | +$5.77M | ﹤0.01% | 2243 |
|
|
2022
Q3 | $116M | Buy |
3,376,210
+792,139
| +31% | +$25.3M | ﹤0.01% | 1865 |
|
|
2022
Q2 | $39.5M | Buy |
2,584,071
+425,509
| +20% | +$6.59M | ﹤0.01% | 2644 |
|
|
2022
Q1 | $49.3M | Buy |
2,158,562
+915,090
| +74% | +$26.2M | ﹤0.01% | 2599 |
|
|
2021
Q4 | $45.8M | Buy |
1,243,472
+299,015
| +32% | +$12.6M | ﹤0.01% | 2709 |
|
|
2021
Q3 | $44.4M | Buy |
944,457
+414,533
| +78% | +$24.4M | ﹤0.01% | 2743 |
|
|
2021
Q2 | $31.9M | Buy |
+529,924
| New | +$22M | ﹤0.01% | 3008 |
|
Other funds holding VERV
GCM
BIG
IA
